Table A2.
Median survival values and rate estimation for each biomarker.
| Molecular Marker | Level of Expression | N = 41 n (%): |
Median Survival | Q1–Q3 | Hazard Ratio | Confidence Interval | p Value |
|---|---|---|---|---|---|---|---|
| HAT-1 | Negative | 1 (2.44) | 60 | 60–60 | |||
| Low/Moderate | 6 (14.63) | 29 | 25–32.2 | 21.743 | [2.908621–162.5435] | 0.003 ** | |
| High | 34 (82.93) | 7.5 | 5–13 | ||||
| IMP-4 | Negative | 1 (2.44) | 60 | 60–60 | |||
| Low/Moderate | 12 (29.27) | 21 | 15.2–28.5 | 8.094 | [3.080211–21.26741] | <0.001 *** | |
| High | 28 (68.29) | 7 | 4–9.5 | ||||
| IMP-5 | Negative | 2 (4.88) | 45 | 37.5–52.5 | |||
| Low/Moderate | 11 (26.83) | 20 | 16–26 | 7.493 | [3.066998–18.30788] | <0.001 *** | |
| High | 28 (68.29) | 7 | 4–9.5 | ||||
| NASP | Negative | 2 (4.88) | 45 | 37.5–52.5 | |||
| Low/Moderate | 10 (24.39) | 21 | 16–27 | 7.563 | [2.927238–19.53798] | <0.001 *** | |
| High | 29 (70.73) | 7 | 4–11 | ||||
| RBBP7 | Negative | 3 (7.32) | 30 | 23–45 | |||
| Low/Moderate | 5 (12.2) | 24 | 20–33 | 4.024 | [1.787804–9.058966] | <0.001 *** | |
| High | 33 (80.49) | 7 | 5–13 | ||||
| H3 | Negative | 6 (14.63) | 31.5 | 25.5–37.5 | |||
| Low/Moderate | 10 (24.39) | 15 | 13–16 | 5.386 | [2.734019–10.60884] | <0.001 *** | |
| High | 25 (60.98) | 6 | 4–8 | ||||
| H4 | Negative | 6 (14.63) | 31.5 | 25.5–37.5 | |||
| Low/Moderate | 9 (21.95) | 14 | 13–16 | 4.932 | [2.481096–9.801876] | <0.001 *** | |
| High | 26 (63.42) | 6.5 | 4–8 | ||||
| ASF-1 | Negative | 2 (4.88) | 46.5 | 39.8–53.2 | |||
| Low/Moderate | 9 (21.95) | 22 | 16–28 | 9.004 | [3.161273–25.64641] | <0.001 *** | |
| High | 30 (73.17) | 7 | 4.25–11 | ||||
| PGAM1 | Negative | 1 (2.44) | 60 | 60–60 | |||
| Low/Moderate | 4 (9.76) | 25 | 21.5–29.2 | 3.681 | [1.402629–9.661442] | <0.001 *** | |
| High | 36 (87.8) | 8 | 5–13.2 | ||||
| AIF-1 | Negative | 3 (7.32) | 24 | 22–42 | |||
| Low/Moderate | 14 (34.15) | 16 | 13.2–20.8 | 3.703 | [2.005442–6.836674] | <0.001 *** | |
| High | 24 (58.54) | 6 | 4–8 | ||||
| IL-12A | Negative | 2 (4.88) | 38 | 27–49 | |||
| Low/Moderate | 9 (21.95) | 20 | 14–28 | 3.473 | [1.694996–7.11442] | 0.001 ** | |
| High | 30 (73.17) | 7 | 4.25–11 | ||||
| IL-18 | Negative | 3 (7.32) | 24 | 19–26 | |||
| Low/Moderate | 10 (24.39) | 13 | 8.25–29 | 1.958 | [1.100421–3.485366] | 0.022 * | |
| High | 28 (68.29) | 7 | 4–13.8 | ||||
| IL-10 | Negative | 13 (31.7) | 4 | 4–7 | |||
| Low/Moderate | 23 (56.1) | 11 | 7–16 | 0.265 | [0.1416624–0.4964779] | <0.001 *** | |
| High | 5 (12.2) | 24 | 20–30 |
Median and interquartile range (Q1–Q3) of each molecular parameter for the different groups of patients (level of expression). Hazard ratio given with p value significance: <0.05 *, <0.01 **, <0.001 ***.